Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 41

1.

Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends Across Risk Groups in the United States, 2010-2015.

Mahal BA, Butler S, Franco I, Spratt DE, Rebbeck TR, D'Amico AV, Nguyen PL.

JAMA. 2019 Feb 11. doi: 10.1001/jama.2018.19941. [Epub ahead of print] No abstract available.

PMID:
30743264
2.

Evolution of the genomic landscape of circulating tumor DNA (ctDNA) in metastatic prostate cancer over treatment and time.

Hahn AW, Stenehjem D, Nussenzveig R, Carroll E, Bailey E, Batten J, Maughan BL, Agarwal N.

Cancer Treat Res Commun. 2019 Feb 6;19:100120. doi: 10.1016/j.ctarc.2019.100120. [Epub ahead of print]

PMID:
30743187
3.

Discovery of deshydroxy bicalutamide derivatives as androgen receptor antagonists.

Kandil S, Lee KY, Davies L, Rizzo SA, Dart DA, Westwell AD.

Eur J Med Chem. 2019 Feb 2;167:49-60. doi: 10.1016/j.ejmech.2019.01.054. [Epub ahead of print]

PMID:
30743097
4.

Best practice in Active Surveillance for men with prostate cancer: A Prostate Cancer UK consensus statement.

Merriel SWD, Hetherington L, Seggie A, Castle JT, Cross W, Roobol MJ, Gnanapragasam V, Moore CM; Prostate Cancer UK Expert Reference Group on Active Surveillance.

BJU Int. 2019 Feb 11. doi: 10.1111/bju.14707. [Epub ahead of print]

PMID:
30742733
5.

Interpreting Oncology Care Model Data to Drive Value-Based Care: A Prostate Cancer Analysis.

Ennis RD, Parikh AB, Sanderson M, Liu M, Isola L.

J Oncol Pract. 2019 Feb 11:JOP1800336. doi: 10.1200/JOP.18.00336. [Epub ahead of print]

PMID:
30742551
6.

Identifying Potentially Avoidable Hospitalizations in Medicare Patients With Prostate Cancer: A Retrospective Analysis.

Parikh AB, Smith W, Sanderson M, Dharmarajan K, Liu M, Isola L, Ennis RD.

J Oncol Pract. 2019 Feb 11:JOP1800560. doi: 10.1200/JOP.18.00560. [Epub ahead of print]

PMID:
30742550
7.

[Prostate cancer prevention. the current trends].

Karpov EI.

Urologiia. 2018 Dec;(6):164-167. Russian.

PMID:
30742397
8.

[Urodynamics study in patients with urinary incontinence, after surgical treatment of localized prostate cancer].

Aboyan IA, Aboyan VE, Orlov YN, Pakus SM, Pakus DI.

Urologiia. 2018 Dec;(6):14-18. Russian.

PMID:
30742372
9.

The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer.

Pagliuca M, Buonerba C, Fizazi K, Di Lorenzo G.

Drugs. 2019 Feb 11. doi: 10.1007/s40265-019-1060-5. [Epub ahead of print] Review.

PMID:
30742279
10.

Characterization of CD133+/CD44+ human prostate cancer stem cells with ATR-FTIR spectroscopy.

Güler G, Guven U, Oktem G.

Analyst. 2019 Feb 11. doi: 10.1039/c9an00093c. [Epub ahead of print]

PMID:
30742170
11.

The induction of core pluripotency master regulators in cancers defines poor clinical outcomes and treatment resistance.

Hepburn AC, Steele RE, Veeratterapillay R, Wilson L, Kounatidou EE, Barnard A, Berry P, Cassidy JR, Moad M, El-Sherif A, Gaughan L, Mills IG, Robson CN, Heer R.

Oncogene. 2019 Feb 11. doi: 10.1038/s41388-019-0712-y. [Epub ahead of print]

PMID:
30742096
12.

Inhibition of Karyopherin beta 1 suppresses prostate cancer growth.

Yang J, Guo Y, Lu C, Zhang R, Wang Y, Luo L, Zhang Y, Chu CH, Wang KJ, Obbad S, Yan W, Li X.

Oncogene. 2019 Feb 11. doi: 10.1038/s41388-019-0745-2. [Epub ahead of print]

PMID:
30742095
13.

Protein Kinase N1 control of androgen-responsive serum response factor action provides rationale for novel prostate cancer treatment strategy.

Venkadakrishnan VB, DePriest AD, Kumari S, Senapati D, Ben-Salem S, Su Y, Mudduluru G, Hu Q, Cortes E, Pop E, Mohler JL, Azabdaftari G, Attwood K, Shah RB, Jamieson C, Dehm SM, Magi-Galluzzi C, Klein E, Sharifi N, Liu S, Heemers HV.

Oncogene. 2019 Feb 11. doi: 10.1038/s41388-019-0732-7. [Epub ahead of print]

PMID:
30742064
14.

IBD as a risk factor for prostate cancer: what is the link?

Sfanos KS, Joshu CE.

Nat Rev Urol. 2019 Feb 11. doi: 10.1038/s41585-019-0157-7. [Epub ahead of print] No abstract available.

PMID:
30742047
15.

The association between physical and mental chronic conditions and napping.

Léger D, Torres MJ, Bayon V, Hercberg S, Galan P, Chennaoui M, Andreeva VA.

Sci Rep. 2019 Feb 11;9(1):1795. doi: 10.1038/s41598-018-37355-3.

16.

Long-Term Implications of a Positive Post Treatment Biopsy Among Patients Treated with External Beam Radiotherapy for Clinically Localized Prostate Cancer.

Zelefsky MJ, Goldman DA, Reuter V, Kollmeier M, McBride S, Zhang Z, Varghese M, Pei X, Fuks Z.

J Urol. 2019 Feb 5. doi: 10.1097/JU.0000000000000110. [Epub ahead of print]

PMID:
30741847
17.
18.

[Prostate cancer is associated with the anogenital distance, a biomarker of prenatal androgen milieu.]

Oñate-Celdrán J, Arense-Gonzalo JJ, Mendiola J, Samper-Mateo P, Sánchez-Rodríguez C, García-Escudero D, Torres-Roca M, Torres-Roca M, Molina-Hernández O, Molina-Hernández O, Adoamnei E, Torres-Cantero AM.

Arch Esp Urol. 2019 Jan;72(1):9-15. Spanish.

PMID:
30741648
19.

Androgen deprivation therapy with chemotherapy or abiraterone for patients with metastatic hormone-naive prostate cancer: a systematic review and meta-analysis.

Sun G, Chen X, Gong U, Chen Y, Li G, Wei F, Jiang A, Niu Y, Shang Z.

Future Oncol. 2019 Feb 11. doi: 10.2217/fon-2018-0619. [Epub ahead of print]

PMID:
30741558
20.

Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: a retrospective study.

Iguchi T, Tamada S, Kato M, Yasuda S, Otoshi T, Hamada K, Yamasaki T, Nakatani T.

Int J Clin Oncol. 2019 Feb 11. doi: 10.1007/s10147-019-01413-1. [Epub ahead of print]

PMID:
30741370

Supplemental Content

Loading ...
Support Center